Clinical study of add on effect of Triphaladaruadi Kwatha (Vangsenokta) along with antidiabetic drug in management of Prameha (Non-Insulin Dependent Diabetes mellitus- NIDDM)

Prameha (Diabetes mellitus) is an age long disease known from vedic period and now it is a leading lifestyle disorder. Diabetes mellitus is a group of metabolic syndromes of fat, protein and carbohydrate which is due to absolute or relative deficiency of insulin. The prevalence of diabetes in India has risen from 7.1% in 2009 to 8.9% in 2019.1 The estimates in 2019 showed that 77 million individuals had diabetes in India, which is expected to rise to over 134 million by 2045.2 In India, it is also 3rd leading cause of death (After heart disease and cancer). The number is projected to be twice by 2030. Type 2 diabetes makes up about 85-90% of all cases. Increase in the overall diabetes prevalence rates largely reflect an increase in risk factors for type 2, notably greater longevity and being overweight or obese. Hence preventive measures are essential and an ideal therapy is still obscure. It remains one of the baffling enigmas for clinical research. This is a randomized single blind standard controlled clinical trial conducted on 66 patients of Prameha (Type II DM & who are on antidiabetic treatment) to rule out Add on effect of Triphaladaruadi kwath of either gender between age group of 40-60 years and grouped into Group A & Group B. 33 patients in group A were on Antidiabetic drug (Metformin 500mg OD/BD and 33 patients in Group B are on same antidiabetic drug (Metformin 500mg OD/BD) with additional Triphaladaruadi kwath (Decoction) for 3 months. Results obtained in subjective and objective parameters were analyzed for the statistical significance by adapting paired ‘t’ test in the groups, Two-way ANOVA test between the groups, and Wilcoxon rank sum test. The study revealed that Group B was found to be more effective in bringing symptomatic relief and improving biochemical markers in the patients of Prameha.